BioCatalystWatch
RVPHWorkspace / RVPH / OverviewCompany library
REVIVA PHARMACEUTICALS HOLDINGS, INC. logo

REVIVA PHARMACEUTICALS HOLDINGS, INC.

REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)

Website

Price
Market cap
Next catalystFDA formulation-strategy feedback expected in Q4 2026brilaroxazine — planned RECOVER-2 · Regulatory meetingSEC filing ↗
Cash

Chart & Events

Candle interval

Core Clinical

D2 receptor × D3 receptor × D4 receptor × 5-HT1A receptor × 5-HT2A receptor × 5-HT2B receptor × 5-HT7 receptor × SERT

PreINDP1P2FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

D2 receptor × D3 receptor × D4 receptor × 5-HT1A receptor × 5-HT2A receptor × 5-HT2B receptor × 5-HT7 receptor × SERT

PreINDP1P2FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

Other pipelines

D2 receptor × D3 receptor × D4 receptor × 5-HT1A receptor × 5-HT2A receptor × 5-HT2B receptor × 5-HT7 receptor × SERT

D2 receptor × D3 receptor × D4 receptor × 5-HT1A receptor × 5-HT2A receptor × 5-HT2B receptor × 5-HT7 receptor × SERT

brilaroxazine (RP5063)

D2 receptor × D3 receptor × D4 receptor × 5-HT1A receptor × 5-HT2A receptor × 5-HT2B receptor × 5-HT7 receptor × SERT

brilaroxazine (RP5063)

D2 receptor × D3 receptor × D4 receptor × 5-HT1A receptor × 5-HT2A receptor × 5-HT2B receptor × 5-HT7 receptor × SERT

PreINDP1P2P3FilingApproved
brilaroxazine (RP5063)

D2 receptor × D3 receptor × D4 receptor × 5-HT1A receptor × 5-HT2A receptor × 5-HT2B receptor × 5-HT7 receptor × SERT

PreINDP1P2P3FilingApproved
brilaroxazine (RP5063)

D2 receptor × D3 receptor × D4 receptor × 5-HT1A receptor × 5-HT2A receptor × 5-HT2B receptor × 5-HT7 receptor × SERT

PreINDP1P2P3FilingApproved

History / paused

D2 receptor × D3 receptor × D4 receptor × 5-HT1A receptor × 5-HT2A receptor × 5-HT2B receptor × 5-HT7 receptor × SERT

PreINDP1P2P3FilingApproved

D2 receptor × D3 receptor × D4 receptor × 5-HT1A receptor × 5-HT2A receptor × 5-HT2B receptor × 5-HT7 receptor × SERT

PreINDP1P2P3FilingApproved

Financial position

Short-term investments

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

RVPH PR & News

PR & News

RVPH SEC archive